POS1080 HYPERLIPIDEMIA IN PSORIATIC DISEASE: HIGHER PREVALENCE IN PSORIATIC ARTHRITIS AND INVERSE ASSOCIATION WITH SYSTEMIC THERAPY

Background:Although the evidence that testifies to a higher prevalence of cardiometabolic risk factors in psoriatic disease is robust, there are not too many studies that have analyzed which disease traits are associated with these risk factors both in psoriasis and psoriatic arthritis1.Objectives:We aimed to analyze the frequency and disease-associated features of hyperlipidemia in psoriatic disease.Methods:Cross-sectional observational study that included 290 patients with psoriatic arthritis (mean age 54 ± 12 years, 54.8 % male, psoriasis average duration 21 ± 10 years) and 310 with psoriasis alone (mean age 53 ± 11.5 years, 52.9% male, psoriasis average duration 22 ± 11 years). We first analyzed the frequency of this comorbidity and then the factors associated with it using conditional logistic regression. The significant factors in this first model were introduced in a multivariate model using a backward stepwise approach.Results:Main disease features are depicted in Table 1. A total of 124 patients had hyperlipidemia (20.7%). Among arthritis patients, 82/290 (28.3%) had hyperlipidemia, compared with 42/310 (13.5%) of those with psoriasis alone (OR 2.5, 95%CI: 1.7–3.3, p < 0.001). Hyperlipidemia was independently associated with age [OR 1.07, 95%CI: 1.04–1.11, p < 0.001] and systemic therapy [OR 0.4, 95%CI: 0.17–0.89, p = 0.026].Conclusion:Hyperlipidemia is common in psoriatic disease, but much more among arthritis patients. This comorbid factor seems to go in parallel with increasing age. There is an inverse association between systemic treatment and hyperlipidemia that should be endorsed with well-designed longitudinal studies.References:[1]Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci 2018; 19: 58.Table 1.Disease characteristics of both subpopulationsVariablePsAn = 290Psoriasisn = 310p-valuesAge (yr ± SD)54 ± 1253 ± 11.5NSAge at psoriasis onset (yr ± SD)32 ± 1631 ± 14.2NSAge at arthritis onset (yr ±SD)46 ± 14NSDuration of psoriasis (yr ± SD)21 ± 1022 ± 11NSDuration of arthritis (yr ± SD)11 ± 7.2NSMale gender (n, %)159 (54.8)164 (52.9)NSPrimary education (n, %)145 (50)148 (47.7)NSSecondary education (n, %)79 (27.2)87 (28.1)NSUniversity degree (n, %)66 (22.8)235 (24.2)NSPlaque psoriasis (n, %)250 (86.2)272 (87.7)NSNail disease (n, %)122 (42.1)110 (35.5)NSPsoriasis in ≥ 3 body areas (n, %)130 (45)155 (50)<0.05Family history of psoriasis (n, %)130 (45)136 (44)NSFamily history of PsA (n, %)44 (15.2)15 (4.8)PASI6.5 ± 4.36.8 ± 3.5Oligoarthritis (n, %)122 (42.1)Polyarthritis (n, %)81 (28)Axial disease (n, %)17 (5.8)Mixed pattern (n, %)70 (24.1)Dactylitis (n, %)87 (30)DIP joint disease (n, %)72 (24.8)Mutilating arthritis (n, %)5 (1.7)Erosive disease (n, %)58 (20)HAQ (mean ± SD)0.74 ± 0.32*BASDAI (mean ± SD)3.64 ± 2.12Pain VAS (mean ± SD)4.09 ± 2.64HLA-B*27 (n, %)52 (17.9)HLA-C*06 (n, %)112 (38.6)124 (40)NSNSAID (n, %)72 (24.8)47 (15.2)NSGlucocorticoids (n, %)34 (11.7)15 (4.8)NSMTX (n, %)189 (65.2)128 (41.3)<0.05Biologics (n, %)128 (44.1)132 (42.6)NSSD, standard deviation; PsA, psoriatic arthritis; PASI, psoriasis area and severity index; DIP, distal interphalangeal joint; HAQ, Health Assessment Questionnaire; BASDAI, bath ankylosing spondylitis disease activity index; VAS, visual analog scale; NSAID, non-steroidal anti-inflammatory drugs. MTX, methotrexate. *Only in patients with axial diseaseDisclosure of Interests:None declared.